Central serous chorioretinopathy associated with the use of spironolactone, aldosterone receptor antagonist.

Abstract

To report a case of central serous chorioretinopathy caused by the use of spironolactone, a competitive antagonist of aldosterone. Case report and review of the literature. A 26-year-old white woman on Aldactone (spironolactone) for the treatment of acne and Adderall (dextroamphetamine/amphetamine) for the treatment of attention deficit hyperactivity disorder, developed central serous chorioretinopathy, which resolved upon discontinuation of spironolactone and remitted after restarting it. It is likely that spironolactone use contributed to the development of central serous chorioretinopathy in this patient. Concomitant use of amphetamine may also have played a role.